CSL and Arcturus Therapeutics Report the EC’s Approval of Kostaive Against COVID-19
Shots:
- The EC has approved Kostaive (ARCT-154) for active immunization to prevent COVID-19 in subjects of age ≥18yrs in the EU & EEA states following CHMP positive opinion in Dec 2024
- Approval was based on Kostaive's clinical data incl. P-I/II/III showing its efficacy & tolerability, plus P-III COVID-19 booster trial depicting superior immunogenicity vs mRNA comparator. Also, follow-up analysis of booster dose showed higher immunogenicity & antibody response for ~12mos. in adults
- Kostaive is a self-amplifying mRNA vaccine that codes for the SARS-CoV-2 spike protein to provide active immunization against COVID-19
Ref: Prnewswire | Image: CSL & Arcturus
Related News:- Arcturus and Meiji Seika Pharma Report the EMA’s Positive Opinion of Kostaive for COVID-19
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
